Proven benefits of angiotensin receptor blockers in the progression of renal disease

European Heart Journal, Supplement

Volumn 5, Issue C, 2003, Pages

  Ruilope, L ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Diabetic nephropathy; INDT; MARVAL; RENAAL; Renal protection; Urinary albumin excretion rates; VALUE

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LOSARTAN; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DRUG CHOICE; DRUG EFFICACY; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; URINARY EXCRETION;

EID: 0037376264     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90044-7     Document Type: Conference Paper

References (20)

1. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001;38:1782-7.
2. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
3. MRC/BHF Heart Protection Study Investigators. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
4. National High Blood Pressure Education Program Working Group. 1995 update of the working group reports on chronic renal failure and renovascular hypertension. National High Blood Pressure Education Program Working Group. Arch Intern Med 1996;156:1938-47.
5. Parving H-H, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
6. Viberti G, Wheeldon NM, for the MARVAL study investigators. Microalbuminuria Reduction with Valsartan in Patients with type 2 Diabetes mellitus. A blood pressure independent effect. Circulation 2002;106:672-8.
7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
8. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861-9.
9. American Diabetes Association. Diabetic nephropathy: a position statement. Diabetes Care 2002;25(suppl 1):S85-9.
10. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355: 1582-7.
11. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
12. Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
13. Dahlöf B, Devereux R, Kjeldsen S et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
14. Cohn JN, Tognoni G, the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-75.
15. de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, Clozel JP. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 2000;1:151-8.
16. Pourdjabbar A, Lapointe N, Rouleau JL. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes? Can J Cardiol 2002;18(suppl A):7A-14A.
17. Lindholm L, Ibsen H, Dahlöf B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;369:1004-10.
18. Julius S. Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Cardiology 1999;91:8-13.
19. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7: 176-83.
20. Kjeldsen S, Julius S, Brunner H et al. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE trial. Blood Press 2001;10:83-91.